यह प्रोटोकॉल मध्यम नैदानिक रूप में प्रस्तुत होने वाले पैराकॉक्सिडिओइडोमाइकोसिस को संबोधित करता है — जो वजन में कमी और सीरोलॉजिकल निष्कर्षों के एक विशिष्ट पैटर्न द्वारा विशेषता है — और इस उप-जनसंख्या पर लागू संरचित उपचार दृष्टिकोण की रूपरेखा प्रस्तुत करता है।
DOI: 10.1590/S0036-46652015000700007
In severe infections, patients present ≥ 3 of the criteria above mentioned; in the moderate form, total body weight loss ranges between 5 and 10% and the counter immunoelectrophoresis titers are between 1/16–1/32.
Recommended treatment for moderate or severe cases of PCM consists in two steps: a) an induction phase to control clinical symptoms until acute phase laboratory parameters return to normal; b) a maintenance phase up to the interruption of treatment based on immunological and other laboratory inflammation markers such as acute phase proteins.
Once the acute phase is under control, the treatment can be changed to oral drugs (once or twice daily), favoring the adherence to longer treatment regimens. For long term treatments, 6–12 months are required for induction and 12–24 months for maintenance.
View source ↗